Addressing the Unmet Needs in Depression Treatment: Key Lessons from Recent Research

Read the full issue

Read the full issue

What a New Systematic Review Tells Us About the Future of Depression Care

Major depressive disorder (MDD) remains one of the leading causes of disability worldwide. While antidepressant prescribing has increased substantially over the past decades, the overall societal burden of depression has not declined in parallel. A newly published systematic review in the Journal of Psychopharmacology sheds light on one potential contributor to this gap: loss of antidepressant responsiveness after treatment interruption.

---

What the Review Examined

The review, “Loss of responsiveness on reinstatement of antidepressants after treatment interruption” (Majkic & Taylor, 2025), systematically assessed existing evidence on patients who:

• Responded to an antidepressant

• Discontinued treatment

• Later restarted the same medication

The central question: Does an antidepressant reliably work again after a break?

---

Key Findings

1. Restarting antidepressants does not always restore benefit

   Across the studies reviewed, 4% to 57% of patients failed to respond when an antidepressant was reinstated after discontinuation — despite having previously benefited from the same drug.

   
   

   This wide range reflects differences in study design, patient populations, and duration of treatment interruption, but the signal is consistent: loss of responsiveness is a real and clinically relevant phenomenon.

   
   

2. Intermittent treatment may contribute to sub-optimal outcomes

   The findings challenge a common clinical assumption that antidepressants can be stopped and restarted without consequence. Instead, treatment interruptions may reduce long-term effectiveness at the individual level and help explain why increased prescribing has not translated into better population-level outcomes.

   
   

3. Adherence is not just a behavioral issue — it’s a pharmacological one

   Non-adherence is often framed as a patient-behavior problem. This review reframes the issue by suggesting that interrupted exposure itself may alter treatment response, independent of patient motivation or intent.

   
   

4. Implications for future treatment strategies

   The authors highlight the need for:

   • Greater awareness of potential loss of efficacy after discontinuation

   • More research into mechanisms behind reduced responsiveness

   • Treatment approaches that support consistent and sustained therapeutic exposure

---

Reference

Majkic N, Taylor D. Loss of responsiveness on reinstatement of antidepressants after treatment interruption – A systematic review. Journal of Psychopharmacology. 2025. DOI: 10.1177/02698811251364388